Extract
Since 2016, chronic obstructive pulmonary disease (COPD) has been the third-leading cause of death worldwide, with an estimated 3 million deaths (5.3% of all deaths), but with large regional variations [1]. Observed data from high-income countries (HICs) [2–5] and modelled data in two global studies [6, 7] have reported declines in COPD mortality rates since the 1990s. Globally, since 2006, modelled COPD mortality rates decreased by 21% [8]. Yet, little is known about observed trends in COPD mortality in Latin America, and more recently in Oceania and Europe.
Abstract
In our international study over 1995–2017, COPD mortality rates declined in most countries. Yet, in females, they remained stable in North America and increased in six countries in Europe. The number of deaths increased or remained stable in most countries. http://bit.ly/2niUQ8d
Footnotes
Disclaimer: Where authors are identified as personnel of the International Agency for Research on Cancer/World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy or views of the International Agency for Research on Cancer/World Health Organization.
Conflict of interest: J. Lortet-Tieulent has nothing to disclose.
Conflict of interest: I. Soerjomataram has nothing to disclose.
Conflict of interest: J.L. López-Campos reports personal fees and non-financial support from AstraZeneca, CSL Behring and Ferrer, and grants, personal fees and non-financial support from Boehringer Ingelheim, Chiesi, Esteve, GebroPharma, GlaxoSmithKline, Grifols, Menarini, Novartis, Rovi and Teva, outside the submitted work.
Conflict of interest: J. Ancochea has nothing to disclose.
Conflict of interest: J.W. Coebergh has nothing to disclose.
Conflict of interest: J.B. Soriano participated in speaking activities, advisory committees and consultancies during the period 2014–2019 sponsored by: Almirall, AstraZeneca, Boehringer-Ingelheim, CHEST, Chiesi, ERS, GEBRO, Grifols, GSK, Linde, Lipopharma, Mundipharma, Novartis, Pfizer, RiRL, Rovi, Sandoz, SEPAR and Takeda. J.B. Soriano declares not receiving ever, directly or indirectly, funding from the tobacco industry or its affiliates.
- Received September 6, 2018.
- Accepted September 25, 2019.
- Copyright ©ERS 2019
LIBRARY USERS
Log in through your institution
Purchase access
